Erasca (ERAS) Announces Positive Preliminary Phase 1 Data for Pan-RAS Molecular Glue ERAS-0015

9 hours ago 1

Maham Fatima

Tue, May 5, 2026 astatine 12:04 PM CDT 2 min read

Erasca Inc. (NASDAQ:ERAS) is 1 of the best performing NASDAQ stocks according to Wall Street analysts. On April 27, Erasca announced affirmative preliminary Phase 1 information for ERAS-0015, a pan-RAS molecular glue targeting coagulated tumors. In patients with non-small compartment lung cancer, the therapy achieved a 62% effect complaint successful late-line settings, rising to 75% for those antecedently treated with platinum therapies. Results for pancreatic crab were besides significant, showing a 50% effect complaint astatine the highest recommended dose of 32 mg daily.

The monotherapy was mostly well-tolerated, with astir broadside effects remaining low-grade and nary treatment-related discontinuations reported. Pharmacokinetic information showed a steady, dose-dependent summation successful exposure, efficaciously reducing tumor DNA crossed each tested patients astatine progressive dose levels. Early findings besides suggest ERAS-0015 tin beryllium safely combined with modular treatments similar panitumumab for colorectal cancer.

Erasca (ERAS) Announces Positive Preliminary Phase 1 Data for Pan-RAS Molecular Glue ERAS-0015

Photo by National Cancer Institute connected Unsplash

Following these results, the institution has narrowed its timeline for disclosing further enlargement and operation cohort information to H1 2027. Monotherapy enlargement and operation trials are already underway successful the US and China. These milestones enactment the company’s efforts to presumption ERAS-0015 arsenic a backbone therapy for a assortment of RAS-mutant cancers.

Erasca Inc. (NASDAQ:ERAS) is simply a California-based clinical-stage precision oncology institution that provides solutions for patients with RAS/MAPK pathway-driven cancers. The company’s halfway therapies see ERAS-0015, ERAS-4001, and ERAS-12.

While we admit the imaginable of ERAS arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey connected Google News.

Read Entire Article